SCF-PCR BRAID™ Dosing Protocol | Chrono-Biological Sequencing for ALS Functional Recovery

Overview

The SCF-PCR BRAID™ Protocol is a precision-timed, multi-drug therapeutic system designed to align treatment delivery with the body’s natural biological rhythms (chronobiology) and disease-state dynamics.

Rather than administering medications uniformly, this protocol:

Synchronizes drug delivery with neuronal vulnerability cycles
Aligns with mitochondrial energy peaks
Minimizes drug–drug interference
Enhances synergistic multi-pathway targeting

This approach transforms conventional ALS treatment into a coordinated biological intervention system.

Core Principle: Chrono-Biological Alignment

Human physiology operates on predictable daily rhythms, including:

Neurotransmitter release cycles
Oxidative stress fluctuations
Immune activity peaks
Mitochondrial energy production windows

The SCF-PCR BRAID™ protocol leverages these rhythms to:

Deliver drugs when they are most effective
Reduce toxicity by avoiding biological mismatch
Improve CNS penetration and response timing

Daily Therapeutic Cycle (24-Hour SCF Sequencing)

Phase 1 — Genetic Suppression Window (Early Morning: 05:00–08:00)

Primary Agent: Tofersen (scheduled dosing days)

Biological Rationale:

Peak transcriptional activity begins in early morning
Optimal timing for gene-silencing mechanisms

SCF Function:

Targets root-cause mutation pathways
Initiates BRAID cascade (F1 Initiator)

Phase 2 — Neuroprotective Stabilization (Morning: 08:00–12:00)

Primary Agents:

Riluzole
Nuedexta

Biological Rationale:

Increased neuronal firing and glutamate activity during waking hours

SCF Function:

Reduces excitotoxic stress
Stabilizes neural signaling networks
Prevents early-day neuronal damage accumulation

Phase 3 — Oxidative Defense Activation (Midday: 12:00–15:00)

Primary Agent:

Edaravone

Biological Rationale:

Midday peak in metabolic activity → increased ROS production

SCF Function:

Neutralizes free radicals
Protects mitochondria during peak metabolic demand

Phase 4 — Organelle Repair & Stress Modulation (Late Afternoon: 15:00–18:00)

Primary Agent:

AMX0035 (PB + TUDCA)

Biological Rationale:

Protein folding stress accumulates throughout the day

SCF Function:

Restores ER–mitochondrial communication
Reduces apoptosis signaling
Prepares system for restorative phase

Phase 5 — Neuroimmune Reset (Evening: 18:00–21:00)

Primary Agent:

Masitinib (if included)

Biological Rationale:

Immune system transitions into regulatory mode

SCF Function:

Suppresses neuroinflammation
Rebalances microglial activity
Prevents overnight inflammatory escalation

Phase 6 — Restorative Regeneration Window (Night: 21:00–02:00)

Supportive Phase (No new primary drug load)

Biological Rationale:

Peak glymphatic clearance
Cellular repair and regeneration during sleep

SCF Function:

Allows full system integration
Enhances CNS detoxification
Supports synaptic repair

Weekly / Cyclical Scheduling Layer

Tofersen (Intrathecal)

Administered per clinical schedule (e.g., loading + maintenance)
Integrated into Phase 1 timing on dosing days

Edaravone

Cyclical dosing (e.g., 14-day cycles)
Maintained within midday oxidative window

Masitinib

Continuous or pulse-based depending on tolerance

SCF Fibonacci-Based Synergy Timing

The BRAID™ protocol uses Fibonacci timing intervals to optimize drug spacing:

1–2–3–5 hour spacing between key agents
Prevents pathway saturation
Maintains dynamic biological responsiveness

Outcome:

Reduced resistance development
Enhanced cross-pathway synergy
Improved pharmacodynamic layering

Patient-Centric Adaptation Layer

Each protocol is customized using SCF diagnostic tools:

Neuroimmune profiling
Metabolic and mitochondrial markers
Genetic mutation status (e.g., SOD1)
Circadian rhythm variability

This allows:

Personalized timing adjustments
Dose optimization
Adaptive sequencing over time

Safety & Monitoring Integration

The protocol incorporates continuous safety oversight:

Liver function monitoring (Riluzole)
Cardiac monitoring (Nuedexta)
Immune markers (Masitinib)
CNS response tracking (Tofersen)

Dosing is dynamically adjusted based on:

Tolerance
Biomarker response
Clinical progression

Why This Matters

Traditional ALS therapies act in isolation.

The SCF-PCR BRAID™ Protocol:

Treats ALS as a multi-system network failure
Applies synchronized intervention across all major disease axes
Uses time as a therapeutic variable, not just dosage

This represents a shift from:

“Single-drug symptom control” → “Coordinated system restoration”

SCF Clinical Positioning

This protocol aligns with:

FDA combination therapy frameworks
Chronotherapeutic drug delivery models
Systems biology–driven precision medicine

It is designed for integration into:

SCF Clinical Programs (Neuroimmune & Regenerative Domains)
SCF Multi-Disciplinary Validation Pipeline

The SCF-PCR BRAID™ Chrono-Biological Protocol represents a next-generation therapeutic architecture—one that recognizes:

Timing is biology
Disease is systemic
Treatment must be synchronized

SCF-PCR BRAID™ Dosing Protocol | Chrono-Biological Sequencing for ALS Functional Recovery

Overview

Rather than administering medications uniformly, this protocol:

Synchronizes drug delivery with neuronal vulnerability cycles
Aligns with mitochondrial energy peaks
Minimizes drug–drug interference
Enhances synergistic multi-pathway targeting

This approach transforms conventional ALS treatment into a coordinated biological intervention system.

Core Principle: Chrono-Biological Alignment

Human physiology operates on predictable daily rhythms, including:

Neurotransmitter release cycles
Oxidative stress fluctuations
Immune activity peaks
Mitochondrial energy production windows

The SCF-PCR BRAID™ protocol leverages these rhythms to:

Deliver drugs when they are most effective
Reduce toxicity by avoiding biological mismatch
Improve CNS penetration and response timing

Daily Therapeutic Cycle (24-Hour SCF Sequencing)

Phase 1 — Genetic Suppression Window (Early Morning: 05:00–08:00)

Primary Agent: Tofersen (scheduled dosing days)

Biological Rationale:

Peak transcriptional activity begins in early morning
Optimal timing for gene-silencing mechanisms

SCF Function:

Targets root-cause mutation pathways
Initiates BRAID cascade (F1 Initiator)

Phase 2 — Neuroprotective Stabilization (Morning: 08:00–12:00)

Primary Agents:

Riluzole
Nuedexta

Biological Rationale:

Increased neuronal firing and glutamate activity during waking hours

SCF Function:

Reduces excitotoxic stress
Stabilizes neural signaling networks
Prevents early-day neuronal damage accumulation

Phase 3 — Oxidative Defense Activation (Midday: 12:00–15:00)

Primary Agent:

Edaravone

Biological Rationale:

Midday peak in metabolic activity → increased ROS production

SCF Function:

Neutralizes free radicals
Protects mitochondria during peak metabolic demand

Phase 4 — Organelle Repair & Stress Modulation (Late Afternoon: 15:00–18:00)

Primary Agent:

AMX0035 (PB + TUDCA)

Biological Rationale:

Protein folding stress accumulates throughout the day

SCF Function:

Restores ER–mitochondrial communication
Reduces apoptosis signaling
Prepares system for restorative phase

Phase 5 — Neuroimmune Reset (Evening: 18:00–21:00)

Primary Agent:

Masitinib (if included)

Biological Rationale:

Immune system transitions into regulatory mode

SCF Function:

Suppresses neuroinflammation
Rebalances microglial activity
Prevents overnight inflammatory escalation

Phase 6 — Restorative Regeneration Window (Night: 21:00–02:00)

Supportive Phase (No new primary drug load)

Biological Rationale:

Peak glymphatic clearance
Cellular repair and regeneration during sleep

SCF Function:

Allows full system integration
Enhances CNS detoxification
Supports synaptic repair

Weekly / Cyclical Scheduling Layer

Tofersen (Intrathecal)

Administered per clinical schedule (e.g., loading + maintenance)
Integrated into Phase 1 timing on dosing days

Edaravone

Cyclical dosing (e.g., 14-day cycles)
Maintained within midday oxidative window

Masitinib

Continuous or pulse-based depending on tolerance

SCF Fibonacci-Based Synergy Timing

The BRAID™ protocol uses Fibonacci timing intervals to optimize drug spacing:

1–2–3–5 hour spacing between key agents
Prevents pathway saturation
Maintains dynamic biological responsiveness

Outcome:

Reduced resistance development
Enhanced cross-pathway synergy
Improved pharmacodynamic layering

Patient-Centric Adaptation Layer

Each protocol is customized using SCF diagnostic tools:

Neuroimmune profiling
Metabolic and mitochondrial markers
Genetic mutation status (e.g., SOD1)
Circadian rhythm variability

This allows:

Personalized timing adjustments
Dose optimization
Adaptive sequencing over time

Safety & Monitoring Integration

The protocol incorporates continuous safety oversight:

Liver function monitoring (Riluzole)
Cardiac monitoring (Nuedexta)
Immune markers (Masitinib)
CNS response tracking (Tofersen)

Dosing is dynamically adjusted based on:

Tolerance
Biomarker response
Clinical progression

Why This Matters

Traditional ALS therapies act in isolation.

The SCF-PCR BRAID™ Protocol:

Treats ALS as a multi-system network failure
Applies synchronized intervention across all major disease axes
Uses time as a therapeutic variable, not just dosage

This represents a shift from:

“Single-drug symptom control” → “Coordinated system restoration”

SCF Clinical Positioning

This protocol aligns with:

FDA combination therapy frameworks
Chronotherapeutic drug delivery models
Systems biology–driven precision medicine

It is designed for integration into:

SCF Clinical Programs (Neuroimmune & Regenerative Domains)
SCF Multi-Disciplinary Validation Pipeline

The SCF-PCR BRAID™ Chrono-Biological Protocol represents a next-generation therapeutic architecture—one that recognizes:

Timing is biology
Disease is systemic
Treatment must be synchronized